2019

Cordella PA

Endotronix Announces Positive Data from the SIRONA First-in-Human Trial for the Cordella™ PA Pressure Sensor System

Lisle, Illinois.  November 18, 2019.  Seroba’s portfolio company, Endotronix, a digital health and medical technology company dedicated to advancing the treatment of chronic heart failure (HF), presented positive first-in-human data of the Cordella™ Pulmonary Artery (PA) Pressure Sensor System (Cordella Sensor).  Data was presented at the 2019 American Heart Association (AHA) Scientific Sessions in Philadelphia, […]

Endotronix Announces Positive Data from the SIRONA First-in-Human Trial for the Cordella™ PA Pressure Sensor System Read More »

Heart Failure

Endotronix Announces Partnership with Tyndall National Institute.

Dublin, Ireland.  October 15, 2019.  Seroba’s portfolio company, Endotronix Ireland Limited, a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), announced today an Enterprise Ireland Industry Partnership project in a collaboration with Tyndall National Institute, a leading European Deep Tech research center in integrated ICT (Information and Communications

Endotronix Announces Partnership with Tyndall National Institute. Read More »

Pq Bypass News

PQ Bypass Announces Unconditional IDE Approval from U.S. FDA for Pivotal Study.

Milpitas, California & Dublin, Ireland.  October 8, 2019.  PQ Bypass Announces Unconditional IDE Approval from U.S. FDA to Start TORUS SFA Stent Graft Pivotal Study (TORUS-2) Seroba’s portfolio company, PQ Bypass, Inc., a clinical-stage medical device company, today announced it has received full approval of its investigational device exemption (IDE) trial of the company’s TORUS

PQ Bypass Announces Unconditional IDE Approval from U.S. FDA for Pivotal Study. Read More »

Heart Failure

Endotronix Closes Expanded Series D Round.

Lisle, Illinois & Dublin, Ireland.  Oct 1, 2019.  Seroba’s investee company, Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure (HF), today announced the expansion of its Series D financing round, bringing the total for the round to $70 million. The expansion syndicate for the LSP-led round includes new

Endotronix Closes Expanded Series D Round. Read More »

Storm

STORM Therapeutics Presents Breakthrough Data at RNA Epigenetics Conference.

Cambridge, UK.  18 September 2019.   STORM Therapeutics, the biotechnology company focused on the discovery of small molecule therapies modulating RNA epigenetics, announced today that Oliver Rausch, Chief Scientific Officer of STORM Therapeutics, will present first of its kind data on targeting RNA modifying enzymes for cancer treatment at its inaugural “RNA Epigenetics in Human

STORM Therapeutics Presents Breakthrough Data at RNA Epigenetics Conference. Read More »

Endotronix 2

FDA Approval for Endotronix Pivotal Trial.

Dublin, Ireland and Lisle, Illinois, USA.  August 1, 2019.  Seroba’s portfolio company, Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced it has received conditional Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin the multi-center PROACTIVE-HF trial

FDA Approval for Endotronix Pivotal Trial. Read More »

Quanta Raises $48 million in Series C Funding Round.

Alcester, Warwickshire, UK.  29 July 2019.  Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a British medical technology company developing a personal haemodialysis system (SC+) for patient use in the clinic and the home, today announced that it has successfully raised £38 million ($48 million) in a first closing of its Series

Quanta Raises $48 million in Series C Funding Round. Read More »

Endotronix 2

Endotronix Enrolls 1st Patient in SIRONA II CE Mark Trial.

Lisle, Illinois.  July 15, 2019.  Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure, today announced enrollment of the first patient in its prospective, multi-center, SIRONA II trial, in Europe.  The 60-patient study will evaluate safety and efficacy of the Cordella™ Pulmonary Artery Pressure Sensor System (Cordella

Endotronix Enrolls 1st Patient in SIRONA II CE Mark Trial. Read More »

Home V2

Seroba Invests in Storm Therapeutics.

Cambridge, UK.  20 May 2019.  STORM Therapeutics (“STORM”), the drug discovery company tackling disease through modulating RNA modifying enzymes, has announced that it has raised an additional £14 million bringing its total Series A financing to £30 million. The financing includes funding from Seroba, as a new investor. STORM’s existing investors, Cambridge Innovation Capital, M

Seroba Invests in Storm Therapeutics. Read More »

Quantasc

Quanta SC+ confirmed as safe and easy to use.

Alcester, Warwickshire, UK.  15 April 2019.  Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a pioneering medical technology company developing a personal haemodialysis system (SC+) for patient use in the clinic and the home, today announced that results from its human factors testing (HFT) of SC+ have been published in Hemodialysis International,

Quanta SC+ confirmed as safe and easy to use. Read More »

We use cookies and analytics to improve your online experience and to help us to understand where our audience is and how they reach us, as well as to understand what topics and site features are of greatest interest.  To find out more, please read our Privacy Policy. By clicking on the Accept button, you consent to our use of cookies and browsing analytics.

Scroll to Top